De novo drug design based on patient gene expression profiles via deep learning

Abstract

Computational de novo drug design is a challenging issue in medicine, and it is desirable to consider all of the relevant information of the biological systems in a disease state. Here, we propose a novel computational method to generate drug candidate molecular structures from patient gene expression profiles via deep learning, which we call DRAGONET. Our model can generate new molecules that are likely to counteract disease‐specific gene expression patterns in patients, which is made possible by exploring the latent space constructed by a transformer‐based variational autoencoder and integrating the substructures of disease‐correlated molecules. We applied DRAGONET to generate drug candidate molecules for gastric cancer, atopic dermatitis, and Alzheimer’s disease, and demonstrated that the newly generated molecules were chemically similar to registered drugs for each disease. This approach is applicable to diseases with unknown therapeutic target proteins and will make a significant contribution to the field of precision medicine.

Artificial Intelligence: A Snapshot of Its Application in Chronic Inflammatory and Autoimmune Skin Diseases

“…Interestingly, an ML-based analysis has been employed to identify alterations in keratinocyte transcriptomic programs in AD and the impact on them of various drugs including Dupilumab, for which ML analysis has been shown to predict indicators of nonresponse using clinical-demographic data as well as enabling a large-scale investigation regarding the impact of sleep-related adverse reactions to such a biological drug [48][49][50]. Regarding the therapeutic aspect, meanwhile, alongside recently reviewed applications of multiple ML models, an important contribution to precision medicine is offered by the most recent advances regarding the use of new DL-based models capable of generating new drug candidate molecules by employing disease-specific gene expression profiles [51,52]. An aspect entirely in step with the times of self-information and self-management, AI, through platforms such as Chat Generative Pre-Trained Transformer (ChatGPT) and specific mobile health apps, has also begun to play a key role in offering patients access to clinically accurate and inclusive information about this condition, however, not without psychopathological implications, especially in parents of children with AD [53][54][55][56].…”

Revolutionizing Personalized Medicine with Generative AI: A Systematic Review

“…In a separate study, (M. developed CSAM-GAN, a generative adversarial network enhanced with sequential channel-spatial attention modules. This method, applied to datasets like lower-grade glioma (LGG) and kidney renal clear cell carcinoma (KIRC) from TCGA, showcased the potential of integrating multimodal data (miRNA expression, mRNA expression, histopathological images) for accurate cancer prognostic outcome prediction.Drug Candidate GenerationThe paper(Yamanaka et al, 2023) introduces a novel computational method named DRAGONET, designed for the generation of potential drug candidates tailored to speci c diseases using patient gene expression pro les and deep learning. DRAGONET leverages gene expression data from patients a icted with a particular disease to discern patterns associated with that ailment.…”